C4 Therapeutics(US:CCCC)2023-03-02 18:01C4 Therapeutics' Strategy and Pipeline - C4 Therapeutics' mission is to deliver on the promise of targeted protein degradation science to create a new generation of medicines that transform patients' lives[20, 114] - The company is focused on progressing multiple small molecule oncology degrader programs in the clinic to improve upon the standard of care[12, 40] - C4 Therapeutics is expanding the application of the TORPEDO platform through existing and new collaboration partners[13, 40] - C4 Therapeutics has a robust clinical pipeline with 4 oncology degraders against targets of high unmet need[20, 114] - An additional program is expected to enter the clinic by the end of 2023[21] CFT7455 (IKZF1/3 Degrader) - The approved IKZF1/3 degrader market is valued at $13 billion[30] - CFT7455 has the potential to become a backbone therapy for multiple myeloma due to its class-leading catalytic activity, selectivity, and high binding affinity[4, 45] - Phase 1 dose escalation data from the Phase 1/2 trials of CFT7455 is expected to be presented in the second half of 2023[40, 115] CFT8634 (BRD9 Degrader) - CFT8634 targets BRD9 for Synovial Sarcoma & SMARCB1-Null Solid Tumors[26, 60] - Phase 1 dose escalation data from the Phase 1/2 trials of CFT8634 is expected in the second half of 2023[40, 88, 115] - In front-line Synovial Sarcoma setting, Progression Free Survival (PFS) is ~7 months, and in relapsed refractory setting, PFS is ~5 months[61] CFT1946 (BRAF V600 Degrader) - CFT1946 targets BRAF-V600 Melanoma, Colorectal (CRC) & Non-Small Cell Lung Cancer (NSCLC)[26, 100] - The approved BRAF inhibitor market is approximately $2 billion[102] - Approximately 70-90% of BRAF mutations are V600[109] - C4 Therapeutics will advance the dose escalation portion of the Phase 1/2 trial and present new preclinical data in the first half of 2023[40, 115] CFT8919 (EGFR L858R Degrader) - CFT8919 targets EGFR L858R for Non-Small Cell Lung Cancer (NSCLC)[26, 111] - The approved EGFR inhibitor market is approximately $6 billion[112] - Osimertinib provides a PFS of 14.4 months for L858R mutations[73, 112] - C4 Therapeutics plans to submit an IND application for CFT8919 in the first half of 2023[113, 115]